Log in

NASDAQ:ALRN - Aileron Therapeutics Stock Price, Forecast & News

+0.01 (+1.41 %)
(As of 02/24/2020 07:20 AM ET)
Today's Range
Now: $0.72
50-Day Range
MA: $0.73
52-Week Range
Now: $0.72
Volume141,864 shs
Average Volume184,915 shs
Market Capitalization$19.95 million
P/E RatioN/A
Dividend YieldN/A
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALRN



Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share


Net Income$-31,550,000.00


Market Cap$19.95 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.05. View Aileron Therapeutics' Earnings History.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aileron Therapeutics.

What price target have analysts set for ALRN?

3 analysts have issued 1-year price objectives for Aileron Therapeutics' stock. Their forecasts range from $5.00 to $6.00. On average, they expect Aileron Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 666.6% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.

What is the consensus analysts' recommendation for Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.

What are Wall Street analysts saying about Aileron Therapeutics stock?

Here are some recent quotes from research analysts about Aileron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. " (1/3/2020)
  • 2. HC Wainwright analysts commented, "Our $6 price target is based on probability-adjusted forecasts for ALRN-6924 for myelopreservation, and ALRN-6924 in combination with Ibrance in MDM2-amplified solid tumor patients." (9/11/2019)

Has Aileron Therapeutics been receiving favorable news coverage?

Media coverage about ALRN stock has been trending very negative on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aileron Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Aileron Therapeutics.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 330,800 shares, a drop of 36.7% from the January 15th total of 522,600 shares. Based on an average daily trading volume, of 357,500 shares, the short-interest ratio is presently 0.9 days. Approximately 2.0% of the company's shares are sold short. View Aileron Therapeutics' Current Options Chain.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
  • Mr. Richard J. Wanstall, VP of Fin. & Operations
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.77%), Blair William & Co. IL (1.25%), Banco Bilbao Vizcaya Argentaria S.A. (0.36%), Geode Capital Management LLC (0.33%) and Game Plan Financial Advisors LLC (0.18%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Bioventures Ltd Novartis, Donald Dougherty, Jeffrey Allen Bailey, John P Phd Longenecker, Kathryn Gregory, Manuel Aivado, Rickenbach Josef H Von and Vojo Vukovic. View Institutional Ownership Trends for Aileron Therapeutics.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Renaissance Technologies LLC, Banco Bilbao Vizcaya Argentaria S.A., Game Plan Financial Advisors LLC and Geode Capital Management LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Donald Dougherty, Jeffrey Allen Bailey, John P Phd Longenecker, Kathryn Gregory, Manuel Aivado, Rickenbach Josef H Von and Vojo Vukovic. View Insider Buying and Selling for Aileron Therapeutics.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.72.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $19.95 million. The company earns $-31,550,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.View Additional Information About Aileron Therapeutics.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is http://www.aileronrx.com/.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]

MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel